Equity Overview
Price & Market Data
Price: $1.74
Daily Change: -$0.132 / 7.59%
Range: $1.61 - $1.87
Market Cap: $19,122,012
Volume: 172,043
Performance Metrics
1 Week: 11.18%
1 Month: 48.25%
3 Months: 43.22%
6 Months: -56.56%
1 Year: -51.30%
YTD: -45.66%
Company Details
Employees: 5
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.